A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere®
The purpose of this protocol is to provide supervised access at this institution to
TheraSphere® treatment for a heterogeneous population of patients with unresectable primary
liver tumors, with the liver being the only dominant site of disease. Based on experience
gained in previous studies and well-established interventional radiology techniques, this
protocol allows multiple treatments with TheraSphere® that may be delivered on an inpatient
or out patient basis. Patients may receive a single dose to the whole liver, or lobar
treatment delivered as a sequence of treatments approximately 30 - 90 days apart. The
investigator, working with co-investigators in radiation oncology, interventional radiology
and nuclear medicine, will develop a specific treatment plan for each patient, based upon
the presenting condition of the patient, the vascular anatomy, and the desired goal of
treatment.
Observational
Observational Model: Case-Only, Time Perspective: Prospective
Evaluate patient quality of life and toxicities associated with TheraSphere® treatment
24 months
Yes
Lawrence Wagman, M.D., F.A.C.S.
Principal Investigator
St. Joseph Hospital of Orange
United States: Institutional Review Board
08-029 TheraSphere®
NCT00877136
February 2009
February 2016
Name | Location |
---|---|
The Center for Cancer Prevention & Treatment at St. Joseph Hospital of Orange | Orange, California 92868 |